Cell-type-specific signalling determines cell fate under physiological conditions, but it is increasingly apparent that also in cancer development the impact of any given oncogenic pathway on the individual cancer pathology is dependent on cell-lineage-specific molecular traits. For instance in colon and liver cancer canonical Wnt signalling produces increased cytoplasmic and nuclear localised beta-catenin, which correlates with invasion and poor prognosis. In contrast, in melanoma increased cytoplasmic and nuclear beta-catenin is currently emerging as a marker for good prognosis, and thus seems to have a different function compared with other cancer types; however, this function is unknown. We discovered that in contrast to its function in other cancers, in melanoma, beta-catenin blocks invasion. We demonstrate that this opposing role of nuclear beta-catenin in melanoma is mediated through MITF, a melanoma-specific protein that defines the lineage background of this cancer type. Downstream of beta-catenin MITF not only suppresses the Rho-GTPase-regulated cell morphology of invading melanoma cells, but also interferes with beta-catenininduced expression of the essential collagenase MT1-MMP, thus affecting all aspects of an invasive phenotype. Importantly, overexpression of MITF in invasive colon cancer cells modifies beta-catenin-directed signalling and induces a 'melanoma phenotype'. In summary, the cell-type-specific presence of MITF in melanoma affects beta-catenin's pro-invasive properties otherwise active in colon or liver cancer. Thus our study reveals the general importance of considering cell-type-specific signalling for the accurate interpretation of tumour markers and ultimately for the design of rational therapies.
Introduction
Deregulations in the Wnt pathway stabilise the overall protein level of beta-catenin, resulting in an increase in cytoplasmic and nuclear localised beta-catenin compared with the normally membrane bound protein (Giles et al., 2003) . Increased cytoplasmic and nuclear beta-catenin is frequently found in different cancer types, but its impact on the individual tumour pathology can differ strikingly. In over 90% of colon cancers the Wnt pathway is deregulated (Giles et al., 2003) and increased nuclear beta-catenin can be found at the invasive front of adenocarcinomas (Jung et al., 2001) . Various studies have identified beta-catenin target genes that contribute to colon cancer progression. Among these are EphB4, the expression of which is increased in colorectal lymph node or liver metastases, or matrix metalloproteinase 7 (MMP-7) (Matrilysin) and S100A4, markers for invasiveness and poor survival (Adachi et al., 2001; Wagenaar-Miller et al., 2004; Stein et al., 2006; Kumar et al., 2009; Boye et al., 2010) . Also, in liver cancer nuclear beta-catenin is correlated with invasion, enhanced metastasis, poor prognosis and reduced disease-free survival (Liu et al., 2010; Zulehner et al., 2010) . In contrast, in melanoma it has been suggested that increased cytoplasmic/nuclear betacatenin expression is linked to a good prognosis and increased overall survival (Bachmann et al., 2005; Chien et al., 2009; Gould Rothberg et al., 2009) . Furthermore, cytoplasmic/nuclear beta-catenin expression has been found to be reduced during progressive disease (Rimm et al., 1999; Kageshita et al., 2001; Omholt et al., 2001; Maelandsmo et al., 2003; Bachmann et al., 2005; PecinaSlaus et al., 2007) . Thus, in melanoma, beta-catenin seems to have a different function compared with other cancer types, but this function is unknown.
Melanoma cells are extremely motile and invasive cells, and like other tumour cells they either invade predominantly by modulating the extracellular matrix through protease activities (such as MMPs) or they invade by undergoing cell-shape changes in order to adjust to the architecture of the 3D-environment (Sahai and Marshall, 2003; Wolf et al., 2003; Sabeh et al., 2009) . The latter mode is less dependent on protease activity and is represented by a round cell-shape, Rho-dependent actin cortex contractions and formation of membrane blebs (Sahai and Marshall, 2003; Fackler and Grosse, 2008) .
The round mode of invasion has also been observed in vivo, and for melanoma cells this morphology appears to be characteristic for cells that are more motile (Wolf et al., 2003; Pinner et al., 2009) . In addition, these more motile melanoma cells are less differentiated (Pinner et al., 2009) . Differentiation of melanocytes and melanoma cells is controlled by the melanocyte-specific transcription factor MITF (Levy et al., 2006) , and transformed melanocytes generally show reduced expression of MITF (Wellbrock et al., 2002 (Wellbrock et al., , 2004 . Importantly, MITF is a beta-catenin target gene in pigment cells (Takeda et al., 2000) , but although beta-catenin expression has been widely analysed in melanoma tissues, the correlation between beta-catenin and MITF expression during human melanoma development is not clear.
For the design of rational therapies, it is crucial to understand mechanisms that underlie the metastatic behaviour of melanoma cells and to characterise highrisk melanoma. Recent studies identify beta-catenin as a promising candidate for a prognostic marker that could help to distinguish between low-risk and highrisk melanoma. However, the function of beta-catenin particularly during the invasive progression of melanoma is unclear, which hampers the precise interpretation of this marker. Here, we show that in contrast to colon or liver cancer, in melanoma high expression of nuclear beta-catenin produces a non-invasive phenotype, which explains beta-catenin's correlation with good prognosis. We identify a melanoma-specific mechanism that clarifies the opposite function of betacatenin and demonstrates the relevance of a cell-typespecific background for the cancer-type-specific role of an oncogenic protein.
Results
Increased cytoplasmic/nuclear beta-catenin suppresses melanoma cell invasion We analysed a panel of melanoma biopsies to assess the correlation of beta-catenin expression with tumour progression, and confirming previous reports (Kageshita et al., 2001; Maelandsmo et al., 2003) we find that there is a decrease in tumours expressing nuclear beta-catenin during tumour progression (Supplementary Figure 1) . However, the most striking finding is that beta-catenin expression is significantly reduced within primary tumours in areas of dermal invasion before cells cluster to nests of cells (Figure 1a ). To further investigate this observation, we used melanoma cell lines expressing high or low levels of cytoplasmic and nuclear localised beta-catenin compared with the predominantly membrane-bound beta-catenin in melanocytes (Figure 1b) .
When in an approach to mimic the in vivo situation, these cells are plated on a thick gel of dermal collagen, high beta-catenin expressing cells (shown are 501mel cells) display high proliferative activity, whereas low beta-catenin-expressing WM266-4 cells divide less frequently (Figure 1c) . Most strikingly though, 501mel cells show an increase in upward growth with cells piling on top of each other on the collagen gel, whereas WM266-4 cells invade the gel (Figure 1c, bottom panel) . Likewise, WM266-4 cells show high invasiveness in a quantitative collagen-invasion assay, but all three high nuclear beta-catenin expressing cell lines display very poor invasive activity (Figure 1d ). This invasive behaviour is not restricted to collagen, and we observe a similar trend when invasion into matrigel (basement membrane) or a collagen/matrigel mixture is analysed (Supplementary Figure 2a) .
Importantly, when beta-catenin expression is reduced in 501mel cells using two different small interfering RNAs (siRNAs), invasion into 3D collagen is increased (Figure 2a) . Furthermore, upregulation of beta-catenin in invasive WM266-4 cells by GSK-3 inhibition suppresses invasion, and this can be significantly rescued when beta-catenin upregulation is prohibited by RNA interference (Figures 2b and c, Supplementary Figure 2) . Together this reveals an anti-invasive function of beta-catenin in melanoma cells.
MITF suppresses invasion downstream of beta-catenin
The particular behaviour of beta-catenin in melanoma suggests that it might function through a target gene specific to melanocytic cells. Such a lineage-specific beta-catenin target is MITF (Takeda et al., 2000) , and indeed, confirming previous findings we find a correlation of MITF expression with betacatenin expression in melanoma biopsies (Figure 2d) . A correlation of high MITF expression with the presence of high beta-catenin levels is also preserved in the nuclear beta-catenin-expressing cell lines (Figure 2d) , and further analysis confirmed that beta-catenin regulates MITF expression in these cells (Supplementary Figure 2e) .
These data suggest a link between upregulated MITF expression in nuclear beta-catenin-expressing cells and suppression of invasion. Indeed, when we reduce MITF expression in 501mel cells using a validated MITFspecific siRNA (Wellbrock et al., 2008) , we observe a strong increase in their invasive activity in 3D collagen (Figure 2e ). In contrast, pre-treatment of WM266-4 with forskolin (FO), a differentiation-inducing agent (Busca and Ballotti, 2000) that upregulates MITF (Figure 2f ), results in significantly decreased invasive activity in a dose-dependent manner (Figure 2f ). This observation is in line with a previous report describing that differentiated melanoma cells are less motile (Pinner et al., 2009) . Although FO elicits numerous effects, when we prevent the FO-induced upregulation of MITF by RNA interference, this results in a partial rescue of the suppressed invasion (Figure 2g ). This clearly demonstrates that upregulation of MITF contributes to the suppression of invasion in differentiated cells. Importantly, when we ectopically overexpress MITF, invasion of WM266-4 cells is suppressed as well, confirming MITF's inhibitory function on invasion (Supplementary Figure 2b) .
MITF suppresses actin-cortex contraction and membrane-bleb formation in 3D Considering their anti-invasive function, we next assessed the effect of beta-catenin and MITF on the regulation of the cytoskeleton dynamics of invading cells. In vivo, motile melanoma cells show a more rounded morphology, whereas non-motile cells are extended and occasionally form 'dendrite'-like extensions (Pinner et al., 2009) . Consistent with this, we find that the majority of the highly invasive WM266-4 cells invade with a round morphology in our 3D-collagen system (Figures 3a and b, Supplementary Figure 3a) . However, when WM266-4 cells are treated with beta-catenin upregulating GSK3 inhibitors, we observe a significant change in morphology with an over 50% reduction in the round phenotype (Figure 3a) . (Figure 3b ), which otherwise produces the round shape. Instead we observe an extended F-actin cortex with filopodia-type protrusions that interact with the collagen through actin-rich focal adhesions (Figure 3b ). These findings suggest that there is a correlation of nuclear beta-catenin, high MITF expression and the suppression of the round blebassociated phenotype. Consistent with this, the majority of high beta-catenin, high MITF expressing 501mel cells show an elongated filopodia phenotype interacting through focal adhesion with the collagen gel (Figure 3c,   Supplementary Figure 3c) . However, when MITF expression is reduced this significantly increases the number of round blebbing cells (Figure 3c and Supplementary Figure  3c) , clearly demonstrating that MITF expression levels control the contraction of the F-actin cortex and the formation of membrane blebs.
MITF regulates the round bleb phenotype in a ROCK-dependent manner At the molecular level, the round bleb-associated cell morphology is regulated by Rho/ROCK-mediated myosin light chain (MLC) phosphorylation, which induces the contraction of the cortical actin meshwork and regulates bleb retraction of cells in 3D (Fackler and Grosse, 2008) . We detect phosphorylated MLC in the F-actin cortex underlying the plasma membrane and within fully formed membrane blebs in WM266-4 cells cultured in 3D collagen (Figure 4a ). However, in the presence of FO and increased MITF expression phospho-MLC in WM266-4 cells is reduced (Figure 4a) . Furthermore, phospho-MLC is low in all nuclear beta-catenin, high MITF expressing melanoma cell lines (Figure 4b ), but when MITF expression is reduced in 501mel cells, we see a significant increase in phospho-MLC (Figure 4c ). This shows that high MITF levels suppress upstream events leading to phosphorylation of MLC.
An important upstream regulator of MLC phosphorylation is the Rho-associated kinase ROCK. Inhibiting ROCK with the small molecule inhibitor Y27632 completely abolishes the positive effect of the MITF Beta-catenin as suppressor of invasion I Arozarena et al knockdown on phospho-MLC (Figure 4c ), which demonstrates that this effect was produced through ROCK, and that high MITF levels suppress ROCK activity towards MLC. It has been previously proposed that MITF might regulate ROCK through the actin nucleator DIA1 (Carreira et al., 2006) . However, we do not find that depleting DIA1 using an ON-TARGETplus siRNA can phenocopy MITF-induced effects on the cell morphology in 3D (Figure 4d ) or ROCK-mediated MLC phosphorylation (Figure 4e ). Thus we find that DIA1 does not regulate ROCK downstream of MITF. The discrepancy between our findings and the previously suggested link might be due to the fact that in the former study actin-cytoskeleton-related effects produced by DIA1 overexpression were analysed in cells on coverslips/2D (Carreira et al., 2006) , which does not necessarily reflect a situation related to 3D (Abbott, 2003) . In line with this, DIA1 has been ruled out to be involved in the regulation of membrane blebs suggesting that other actin nucleators are having a role (Charras and Paluch, 2008) . Thus, the detailed mechanism, as to how MITF suppresses ROCK activity in melanoma cells in a 3D environment is still unclear, and is subject of current investigations.
MMP expression is reduced in high MITF expressing melanoma cells
In line with the observation that high MITF levels suppress ROCK activity towards MLC, in 501mel cells ROCK activity towards MLC is low and Y27632 does not have any significant effect on MLC phosphorylation or the phenotype of 501mel cells (Figures 5a and  b) . However, inhibition of ROCK in WM266-4 cells has a significant effect on phospho-MLC and converts the morphology from a round bleb phenotype to the more elongated phenotype (Figures 5a and b) , indicating that ROCK activity is required for the phospho-MLC-mediated cortex contraction and the round bleb-associated phenotype. The difference in ROCK activity in 501mel and WM266-4 cells is also seen in the ability of Y27632 to block the invasion of WM266-4 cells, whereas the invasion of 501mel cells is not significantly affected (Figure 5c ). Cells that do not invade via Rho/ROCK activities use proteases such as MMPs in order to modulate the extracellular matrix for invasion, and indeed the invasion of 501mel cells is strongly reduced when proteolytic activities are inhibited (Figure 5d ). This indicates that 501mel cells use proteases for invasion, but this does not explain why WM266-4 cells are still more invasive than 501mell cells, even when their ROCK-mediated cytoskeleton dynamics are blocked by Y27632 (Figure 5c ). This led us to analyse MMP activity in the two cell lines.
Zymography of WM266-4 and 501mel cells shows that MMP-2 is present in the medium of WM266-4 cells at much higher levels when compared with 501mel cells (Figure 5e ). In addition we detect predominantly cleaved active MMP-2 in the medium of WM266-4 cells, whereas 501mel cells secrete mainly the non-processed inactive form proMMP-2 (Figure 5e ).
Cleaved, activated proMMP-2 is produced by the membrane-anchored MT1-MMP, but importantly, MT1-MMP is also a collagenase and as such essential for cancer cell invasion (Sabeh et al., 2004; Itoh, 2006) . We find that MT1-MMP expression is significantly lower in 501mel than in WM266-4 cells (Figure 5f ), which is in line with the amount of active MMP-2 levels detected in the medium of the cells (Figure 5e ). Moreover, lower MT1-MMP expression is detectable in all nuclear beta-catenin cell lines (Figure 5f ).
Increased MITF expression suppresses beta-catenininduced MT1-MMP expression in melanoma cells
The low amounts of MT1-MMP mRNA in all nuclear beta-catenin cell lines is rather surprising, as in colon cancer cells MT1-MMP has been identified as a betacatenin-dependent TCF/LEF target gene (Hlubek et al., 2004) . More strikingly, we find that also in WMM266-4 cells MT1-MMP expression is dependent on betacatenin (Figure 6a ), suggesting that its regulation is conserved in melanoma cells. Accordingly, in 501mel cells, beta-catenin depletion also reduces the levels of MT1-MMP expression (Figure 6a ). However, despite the fact that these cells express higher amounts of nuclear beta-catenin, its contribution to MT1-MMP expression is much lower than in WM266-4 cells. This seemingly contradicting difference between melanoma and colon cancer cells could be due to the presence of MITF in melanoma cells, because MITF can recruit beta-catenin to MITF target genes by directly binding to it (Schepsky et al., 2006) . As a result of this recruitment and interaction, MITF could interfere with the regulation of beta-catenin at TCF/LEF target genes. Because MITF expression is highly increased in 501mel cells, we asked whether such a mechanism could explain the regulation of MT1-MMP in these cells. We can confirm that beta-catenin is present in MITF immunoprecipitates from 501mel cells (Figure 6b ). Furthermore, MITF depletion from 501mel cells results in a significant increase in the transcriptional activity from a generic TCF/LEF-regulated promoter (Figure 6c ). Most importantly, however, a similar situation is found for endogenous MT1-MMP expression (Figure 6d ). In line with this inhibitory effect of MITF in 501mell cells, we find that when WM266-4 cells are treated with FO-which increases MITF expression-MT1-MMP expression is significantly reduced (Figure 6e ). Together these data show that high MITF expression levels can interfere with beta-catenin-directed transcription, and this results in suppression of MT1-MMP expression by MITF.
MITF induces a 'melanoma phenotype' in nuclear beta-catenin-expressing colon cancer cells Finally, we wanted to investigate whether MITF's 'modifier' function can explain the difference of beta-catenin's role in melanoma compared with other cancer types such as colon cancer. We therefore analysed the effect of ectopic MITF expression on SW480 colon cancer cells, which are homozygous for an APC mutation (Kawasaki et al., 2003) . As a consequence SW480 cells express increased amounts of nuclear beta-catenin ( Figure 7a ) and importantly, ectopically expressed MITF co-localises with nuclear beta-catenin in SW480 cells (Figure 7a ). Like WM266-4 cells, SW480 cells display a round phenotype with the formation of membrane-bleb protrusions when cultured on a 3D collagen gel (Figure 7b ). However, when MITF is expressed in SW480 cells this results in a complete change in morphology to an elongated cell body and the formation of focal adhesion-like protrusions in a significant proportion of cells (Figure 7b ), suggesting that also in colon cancer cells MITF suppresses membrane-bleb protrusions and affects the actin cytoskeleton. Furthermore, we find that MITF interferes with beta-catenin-directed transcription in SW480 cells (Figure 7c ) and therefore also suppresses the beta-catenin-target gene MT1-MMP expression (Figure 7d) . Thus, MITF regulates cellular events in nuclear beta-catenin-expressing colon cancer cells comparable to melanoma cells. 
Discussion
We have identified a mechanism that demonstrates that in order to understand the cellular outcome of a genetic lesion in cancer cells, it is essential to consider the cell-type-specific background. In particular, our data provide an explanation for the opposing function of beta-catenin in malignant melanoma when compared with colon or liver cancer.
The role of beta-catenin in melanoma has been a matter of debate for a long time, because initial findings proposed a situation similar to colon cancer, where mutated-activated beta-catenin drives tumour progression (Rubinfeld et al., 1997) . However, it is now convincingly established that increased cytoplasmic and nuclear beta-catenin expression is linked to a good prognosis (Omholt et al., 2001; Bachmann et al., 2005; Chien et al., 2009; Gould Rothberg et al., 2009) . Nevertheless, we and others find nuclear beta-catenin in a considerable amount of primary melanomas (Kageshita et al., 2001; Omholt et al., 2001; Maelandsmo et al., 2003; Bachmann et al., 2005) , which suggests that it might contribute to early events in melanoma development. However, the role of beta-catenin in melanoma initiation is not clear, because suggested functions in bypassing senescence and regulating proliferation (Widlund et al., 2002) appear to be not prevalent in the human disease situation, where increased nuclear beta-catenin is found in the majority of benign 'senescent' nevi and in tumours with low proliferative index (Kageshita et al., 2001; Bachmann et al., 2005; Demirkan et al., 2007; Chien et al., 2009) . It thus seems that the presence of increased cytoplasmic and nuclear beta-catenin in early stages of melanoma development might not be the cause, but rather the consequence of this cancer type originating from melanocytic cells. Here, it is important to mention that canonical Wnt signalling is an essential regulator of melanocyte proliferation and differentiation in the epidermis (Yamaguchi et al., 2004) . The fact that the majority of benign nevi express increased cytoplasmic and nuclear beta-catenin could thus simply reflect that differentiation signalling is strongly switched on in these benign lesions, which usually are highly pigmented. This would suggest that canonical Wnt signalling predominantly regulates differentiation in melanocytic cells, and is in line with the fact that Wnt3a induces the expression of differentiation-related genes even in melanoma cells (Chien et al., 2009) . In this context, it is important to mention that non-canonical Wnt signalling (specifically WNT5A) is activated during melanoma progression and most crucially, non-canonical Wnt signalling can suppress canonical Wnt signalling (O'Connell and Weeraratna, 2009), which as we have shown results in increased invasiveness.
As mentioned above cytoplasmic and nuclear betacatenin is frequently expressed in primary melanomas, but in line with others we find that this expression decreases during progressive disease (Kageshita et al., 2001; Maelandsmo et al., 2003; Bachmann et al., 2005) . Importantly, this mirrors the pattern described for MITF expression (Salti et al., 2000; Nazarian et al., 2010) . Moreover, we see that MITF expression levels correlate with beta-catenin in melanoma samples, which is consistent with the fact that beta-catenin regulates MITF expression in melanoma cells (Widlund et al., 2002) . Furthermore, in line with the reported detection of reduced beta-catenin and MITF expression during tumour progression, we show that lowering beta-catenin expression in melanoma cells increases their invasiveness, and we identify MITF downstream of beta-catenin as suppressor of invasion. This finding is entirely in agreement with the fact that very-low MITF expression levels are associated with a more invasive phenotype and an invasive gene signature in human melanoma (Hoeck et al., 2008) .
Our data demonstrate that MITF can interfere with the cellular program of a cancer cell. In particular we reveal a mechanism, in which MITF controls the signalling output downstream of beta-catenin (Figure 8 ). In cells expressing low amounts of cytoplasmic/ nuclear beta-catenin, MITF expression is low and does not interfere with beta-catenin-directed transcription of MT1-MMP; this results in high protease activity (Figure 8b ). In addition, ROCK is not inhibited, which results in MLC phosphorylation, actin-cortex contraction and a round, membrane-bleb phenotype (Figure 8b ). Cells with this morphology are more motile and their invasion is less restricted by proteolytic activities (Sahai and Marshall, 2003) . However, the expression of increased nuclear beta-catenin results in high MITF levels (Figure 8a ), which blocks beta-catenininduced MT1-MMP expression and inhibits ROCK activity, resulting in an elongated morphology (Figure 8a ). Cells with this morphology require proteolytic activity for invasion (Sahai and Marshall, 2003) and the low expression of MT1-MMP results in cells with low invasive potential. Importantly, although these processes are seen in melanoma cells, the same mechanisms apply to colorectal cancer cells after forced overexpression of MITF, thus demonstrating the crucial role of MITF in regulating the cellular program of a cancer cell.
Materials and methods
Cell culture, reagents and transfection procedures Primary human melanocytes were grown as described (Wellbrock et al., 2008) . 501mel, 888mel, 1290mel cells (Robbins et al., 1995) , A375, WM266-4 and SW480 cells were grown in DMEM/10% FCS (Invitrogen, Carlsbad, CA, USA). All melanoma cell lines were established from metastatic tumours. FO and Hoechst-53342 were from Sigma-Aldrich (St Louis, MO, USA), Cy-5-Phalloidin from Invitrogen and Y27632 from Tocris (Elisville, MO, USA). RNA interference transfections used 10-40 nM siRNA oligonucleotides. The verified MITF siRNA has been described (Wellbrock et al., 2008) . Further siRNA oligonucleotides were from Qiagen (Valencia, CA, USA) (bcat1: 5 0 -AACCACUAAUGUCCAGC GUUU-3 0 and bcat2: 5 0 -AAGUGGGUGGUAUAGAGGC UC-3 0 ). The ON-TARGET-plus DIA1 SMART-pool was from Dharmacon (Thermofisher, Epsom, UK). SW480 cells were transfected with pEF-MITF (Wellbrock et al., 2008) . To culture cells on thick collagen layers, cells were seeded on a 12-well containing 0.6 ml (2.3 mg/ml) fibrillar bovine dermal collagen (Nutacon, Leimuiden, The Netherlands, 2.3 mg/ml).
Immunoblots and antibodies
Cell lysates were prepared as described (Wellbrock et al., 2008) and analysed by standard western-blotting protocols. For immunoprecpitation, MITF was precipitated from 1 mg of total protein using 2 mg of MITF (D5) antibody. The primary antibodies used were: MITF: D5, C5 (Thermofisher); beta-catenin: E-5, ERK2: C-14 and beta-tubulin: H-235 Santa Cruz Biotechnology (Santa Cruz, CA, USA), phospho-MLC2 (Ser19) (Cell Signalling, Boston, MA, USA).
Immunofluorescence and microscopy Cells on cover slips were stained as described (Wellbrock and Marais, 2005) . Cells on collagen were formalin fixed and incubated with antibodies or phalloidin for 3 h, respectively. Nuclei were stained with Hoechst 53342, and collagen plugs were mounted on slides using DABCO (Sigma-Aldrich). For conventional fluorescence microscopy a Zeiss Axiovert 200 (Zeiss, Jena, Germany) equipped with epifluorescence was used; images were taken by a Photometrics Cool Snap HQ CCD camera (Photometrix, Wales, UK) driven by Metamorph software (Universal Imaging, Wokingham, UK). GFP-expressing cells were monitored using a Leica DM IL HC inverted microscope and a FC340 Cooled Monocrome camera (Leica Microsysytems, Milton Keynes, UK). For 3D reconstructions, cells were analysed using a Delta Vision RT (Applied Precision, Issaquah, WA, USA) restoration microscope. Images were collected by a Coolsnap HQ (Photometrics) camera with a Z optical spacing of 1 mm. Raw images were then deconvolved using the Softworx software (Applied Precision), and ImageJ NIH (Bethesda, MD, USA) was used for the 3D reconstruction.
In vitro invasion assays Invasion assays analysing melanoma cell invasion into collagen (Nutacon, 2.3 mg/ml) or Cultrex basement membrane (R&D, Minnneapolis, MN, USA, 15.83 mg/ml), were carried out as described (Arozarena et al., 2011) . The cocktail of protease inhibitors was prepared as described (Sahai and Marshall, 2003) : 20 mM GM6001 (Calbiochem, EDM Chemicals, Gibbstown, NJ, USA), 10 mM calpeptin (Calbiochem) and 10 mg/ml aprotinin and leupeptin (Sigma). Data are from at least three independent measurements and are shown as mean ± s.e.m.; if not otherwise indicated, differences between treatments and controls were analysed by an unpaired t-test.
Gelatin zymography
An equal number of 501mel or WM266.4 cells were seeded on top of collagen gels and after 72 h aliquots of conditioned media were mixed with non-reducing sample buffer and analysed on gelatin containing (1.2 mg/ml) acrylamide gels. Gels were stained with 0.025% Coomassie and then destained until bands were visualised.
Quantitative real-time PCR RNA was isolated with TRIZOL (Invitrogen) and selected genes were amplified by quantitative real-time PCR using SYBR green (Qiagen). Primers sequences were MITF: 5 0 -CCGTCTCTCACTGGATTGGT, TACTTGGTGGGGTTT TCGAG-3 0 ; MT1-MMP: 5 0 -CCGAGGGCTTCCATGGC-GAC-3 0 , 5 0 -ATTCCTGACAGTCCAAGGCTCGGC-3 0 ; GA PDH: 5 0 -CAATGACCCCTTCATTGACC-3 0 , 5 0 -GACAAGC TTCCCGTTCTCAG-3 0 . Data are from three independent experiments and are shown as mean ± s.e.m.; differences between treatments and controls were analysed by an unpaired t-test.
Luciferase reporter assays Cells were transfected with 0.6 mg of TOPFLASH-reporter construct (van de Wetering et al., 1997), 0.3 mg of pEF-MITF and 0.3 mg of pcmv-renilla. For RNA interference, 80 nM siRNA was co-transfected with the plasmids. Cells were analysed for luciferase activity after 48 h using a Firefly and Renilla Luciferase kit (Cambridge Bioscience, Cambridge, UK). The data are corrected for Renilla luficerase and represent the activity for assays carried out in triplicate, with error bars to represent standard erros from the mean. Data are from three independent experiments and are shown as mean±s.e.m.; differences between treatments and controls were analysed by an unpaired t-test.
Immunohistochemistry
From sample archives of USZ 21 blocks of paraffin-embedded formalin-fixed melanoma tissues were selected including primary tumours (9), skin metastases (6), one lymphnode metastasis and one lung metastasis. Tissue sections of 1 mm were obtained, and immunostaining for beta-Catenin (Transduction Laboratories, BD Biosciences, Oxford, UK, 1:200) and MITF (Zytomed Systems, Berlin, Germany, 1:60) was assessed using the APAAP method on DAKO Autostainer Beta-catenin as suppressor of invasion I Arozarena et al
